Form 4: Bristol-Myers Squibb Director Derica W. Rice Reports Acquisition of Deferred Share Units

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Summary

• On March 31, 2024, Derica W. Rice, a director of Bristol-Myers Squibb, reported the acquisition of 691.499 deferred share units.
• These units are convertible into shares of common stock upon settlement, which occurs when Rice ceases to be a director or at a previously specified future date.
• The price of the derivative security is $54.23.
• Following the transaction, Rice beneficially owns 23,634.109 derivative securities.
• These include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions, neither particularly positive nor negative.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, in their own company's stock. This allows the public to monitor insider sentiment and potential alignment with shareholder interests.

Stakeholder Impact

• The acquisition of deferred share units by a director signals alignment with the company's long-term performance, potentially reassuring shareholders.

Key Dates